Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir

AIDS. 2005 Sep 2;19(13):1433-4. doi: 10.1097/01.aids.0000180791.85003.3b.

Abstract

We describe the hepatotoxicity encountered in a cohort of HIV-positive patients treated with lopinavir/ritonavir. We used the database from the SCOLTA project, an on-line pharmacovigilance programme involving 25 Italian infectious disease centres. A total of 755 patients were followed, over a mean observation period of 16 months. The incidence of severe events was low despite the high prevalence of patients co-infected with hepatitis virus at enrollment.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Chemical and Drug Induced Liver Injury*
  • Female
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / adverse effects*
  • Hepatitis B, Chronic / complications
  • Hepatitis C, Chronic / complications
  • Humans
  • Incidence
  • Italy / epidemiology
  • Liver Diseases / epidemiology
  • Lopinavir
  • Male
  • Middle Aged
  • Product Surveillance, Postmarketing
  • Pyrimidinones / adverse effects*
  • Ritonavir / adverse effects*

Substances

  • HIV Protease Inhibitors
  • Pyrimidinones
  • Lopinavir
  • Ritonavir